Protein Corona on Brain Targeted Nanocarriers: Challenges and Prospects

Adv Drug Deliv Rev. 2023 Oct 10:115114. doi: 10.1016/j.addr.2023.115114. Online ahead of print.ABSTRACTSafe and efficient medical therapy for brain diseases is still an unmet clinical need due to various barriers represented by the blood-brain barrier. Well-designed brain targeted nanocarriers are potential solutions for enhanced brain drug delivery; however, the complicated in vivo process attenuates performance of nanocarriers, which severely hampers clinical translation. The formation of protein corona (PC) is inevitable for nanocarriers circulation and transport in biofluids, acting as an important factor to regulate in vivo performance of nanocarriers. In this review, the reported strategies have been retrospected to promote understanding on current situation in developing brain targeted nanocarriers. The interplay between brain targeted nanocarriers and plasma proteins is emphasized to comprehend how the nanocarriers adsorbed proteins by certain synthetic identity, and following regulations on in vivo performance of nanocarriers. More importantly, the mainstream methods to promote efficiency of nanocarriers by regulating PC, defined as in vitro functionalization and in vivo functionalization strategies, are also discussed. Finally, viewpoints about future development of brain targeted nanocarriers according to the understanding on nanocarriers-PC interaction are proposed.PMID:37827336 | DOI:10.1016/j.addr.2023.115114
Source: Advanced Drug Delivery Reviews - Category: Drugs & Pharmacology Authors: Source Type: research